PREDICTIVE BIOMARKER OF TUMOR-INFILTING LYMPHOCYTE THERAPY AND ITS APPLICATION

摘要

The present invention relates to a biomarker useful in adoptive cell therapy. The biomarker in question is CD150, otherwise called SLAM or SLAMF1. In this application, we demonstrate that the expression of CD150 on infusion products from tumor-infiltrating lymphocytes correlates with the response rate observed in these patients. High expression of CD150 is found in patients who show a complete response, and low expression is found in patients who do not respond to therapy. The invention relates to the use of a biomarker for predicting response rates or stratification of patients for treatment. The invention also encompasses the use of this receptor in adoptive cell therapy regimens in general, including overexpression of the receptor in populations of T cells or the isolation of cells expressing CD150, in order to increase efficacy.